Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2020 06:30 ET | Source: Veru Inc.

Veru Reports Record Fiscal 2020 Fourth Quarter and Record Full-Year Financial Results

—FY20 Full-Year Net Revenues and Gross Profit Achieve Historical Highs of $43 Million and $31 Million, Respectively— —Robust Growing Prescription Sales of FC2 Key Growth Driver; Product...
November 23, 2020 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2020 Fourth-Quarter, Full-Year Financial Results, Host Conference Call on December 9th

MIAMI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
September 29, 2020 08:30 ET | Source: Veru Inc.

Veru Completes Enrollment of Phase 2 Clinical Trial of VERU-111, Novel Oral Drug for Metastatic Prostate Cancer

MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate...
September 18, 2020 07:30 ET | Source: Veru Inc.

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program— MIAMI, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on...
September 09, 2020 08:30 ET | Source: Veru Inc.

Veru to Participate and Present at Four Upcoming Healthcare Investor Conferences

MIAMI, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate...
August 18, 2020 08:30 ET | Source: Veru Inc.

Veru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product

-- Three-Year Multi-Million Unit Extension Agreement – -- Roman Swipes Seeing Rapid Growth through Leading Men’s Digital Health Clinic -- MIAMI, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc....
August 13, 2020 06:30 ET | Source: Veru Inc.

Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

--Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021-- --VERU-111 Phase 1b Clinical Trial...
August 04, 2020 08:30 ET | Source: Veru Inc.

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model-- --VERU-111’s ability to disrupt microtubules has potential for...
July 30, 2020 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
July 27, 2020 08:30 ET | Source: Veru Inc.

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...